167 related articles for article (PubMed ID: 12218297)
41. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.
Nekarda H; Schlegel P; Schmitt M; Stark M; Mueller JD; Fink U; Siewert JR
Clin Cancer Res; 1998 Jul; 4(7):1755-63. PubMed ID: 9676852
[TBL] [Abstract][Full Text] [Related]
42. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
Harbeck N; Kates RE; Schmitt M
J Clin Oncol; 2002 Feb; 20(4):1000-7. PubMed ID: 11844823
[TBL] [Abstract][Full Text] [Related]
43. Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study.
Horvatić Herceg G; Herceg D; Kralik M; Bence-Zigman Z; Tomić-Brzac H; Kulić A
Wien Klin Wochenschr; 2006 Oct; 118(19-20):601-9. PubMed ID: 17136335
[TBL] [Abstract][Full Text] [Related]
44. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
45. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and -2 in hepatocellular carcinoma.
Zhou L; Hayashi Y; Itoh T; Wang W; Rui J; Itoh H
Pathol Int; 2000 May; 50(5):392-7. PubMed ID: 10849328
[TBL] [Abstract][Full Text] [Related]
46. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
[TBL] [Abstract][Full Text] [Related]
47. Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas.
Osmak M; Babić D; Abramić M; Milicić D; Vrhovec I; Skrk J
Neoplasma; 2001; 48(6):462-7. PubMed ID: 11949838
[TBL] [Abstract][Full Text] [Related]
48. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.
De Cremoux P; Grandin L; Diéras V; Savignoni A; Degeorges A; Salmon R; Bollet MA; Reyal F; Sigal-Zafrani B; Vincent-Salomon A; Sastre-Garau X; Magdelénat H; Mignot L; Fourquet A;
Anticancer Res; 2009 May; 29(5):1475-82. PubMed ID: 19443353
[TBL] [Abstract][Full Text] [Related]
49. [Effects of urokinase type plasminogen activator and plasminogen activator inhibitor-1 expressions on the formation of aneurysm of perimembranous ventricular septal defect].
Qian J; Li B; Yin M; Shen P; Sun K
Zhonghua Er Ke Za Zhi; 2015 Jun; 53(6):453-8. PubMed ID: 26310557
[TBL] [Abstract][Full Text] [Related]
50. Differential prognostic impact of uPA and PAI-1 in colon and rectal cancer.
Langenskiöld M; Holmdahl L; Angenete E; Falk P; Nordgren S; Ivarsson ML
Tumour Biol; 2009; 30(4):210-20. PubMed ID: 19776673
[TBL] [Abstract][Full Text] [Related]
51. The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis.
Pappot H; Pedersen AN; Brünner N; Christensen IJ
Lung Cancer; 2006 Feb; 51(2):193-200. PubMed ID: 16325301
[TBL] [Abstract][Full Text] [Related]
52. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
Offersen BV; Pfeiffer P; Andreasen P; Overgaard J
Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889
[TBL] [Abstract][Full Text] [Related]
53. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
[TBL] [Abstract][Full Text] [Related]
54. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
55. The role of urokinase-type plasminogen activator and its inhibitor PAI-1 in gastric cancer.
Herszényi L; Plebani M; Cardin R; Carraro P; De Paoli M; Roveroni G; Naccarato R; Farinati F
Acta Physiol Hung; 1995; 83(3):213-21. PubMed ID: 8852646
[TBL] [Abstract][Full Text] [Related]
56. Plasminogen activators in oesophageal carcinoma.
Hewin DF; Savage PB; Alderson D; Vipond MN
Br J Surg; 1996 Aug; 83(8):1152-5. PubMed ID: 8869332
[TBL] [Abstract][Full Text] [Related]
57. Serine proteinase activation in esophageal cancer.
Tang WH; Friess H; Kekis PB; Martignoni ME; Fukuda A; Roggo A; Zimmerman A; Büchler MW
Anticancer Res; 2001; 21(4A):2249-58. PubMed ID: 11724279
[TBL] [Abstract][Full Text] [Related]
58. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
59. Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.
Herszényi L; Farinati F; Cardin R; István G; Molnár LD; Hritz I; De Paoli M; Plebani M; Tulassay Z
BMC Cancer; 2008 Jul; 8():194. PubMed ID: 18616803
[TBL] [Abstract][Full Text] [Related]
60. Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients.
Halamkova J; Kiss I; Pavlovsky Z; Jarkovsky J; Tomasek J; Tucek S; Hanakova L; Moulis M; Cech Z; Zavrelova J; Penka M
Hepatogastroenterology; 2011; 58(112):1918-25. PubMed ID: 22234062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
